Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Context Therapeutics Inc (CNTX)

Context Therapeutics Inc (CNTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 21,719
  • Shares Outstanding, K 15,970
  • Annual Sales, $ 0 K
  • Annual Income, $ -23,960 K
  • 60-Month Beta 2.17
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.90
Trade CNTX with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.38
  • Number of Estimates 2
  • High Estimate -0.32
  • Low Estimate -0.45
  • Prior Year -0.40
  • Growth Rate Est. (year over year) +5.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1700 +16.24%
on 03/25/24
1.6000 -15.00%
on 04/11/24
+0.1950 (+16.74%)
since 03/22/24
3-Month
0.8900 +52.81%
on 01/25/24
1.6000 -15.00%
on 04/11/24
+0.3150 (+30.14%)
since 01/22/24
52-Week
0.4700 +189.36%
on 05/15/23
1.6900 -19.53%
on 07/03/23
+0.7500 (+122.95%)
since 04/21/23

Most Recent Stories

More News
Context Therapeutics and The Menarini Group Announce Clinical Trial Collaboration and Supply Agreement to Evaluate ONA-XR and Elacestrant Combination

/PRNewswire/ -- Context Therapeutics Inc. ("Context" or the "Company") (Nasdaq: CNTX), a women's oncology company developing small molecule and immunotherapy...

CNTX : 1.3600 (+3.03%)
Context Therapeutics and The Menarini Group Announce Clinical Trial Collaboration and Supply Agreement to Evaluate ONA-XR and Elacestrant Combination

/CNW/ -- Context Therapeutics Inc. ("Context" or the "Company") (Nasdaq: CNTX), a women's oncology company developing small molecule and immunotherapy...

CNTX : 1.3600 (+3.03%)
Context Therapeutics and The Menarini Group Announce Clinical Trial Collaboration and Supply Agreement to Evaluate ONA-XR and Elacestrant Combination

Preclinical data support the potential of ONA-XR plus estrogen receptor degraders in endocrine resistant disease models Context to initiate Phase 1b/2...

CNTX : 1.3600 (+3.03%)
Context Therapeutics® Reports First Quarter 2022 Operating and Financial Results

Abstract on results of the monotherapy portion of Phase 2 ONA-XR clinical trial in granulosa cell tumors of the ovary accepted for oral presentation at the...

CNTX : 1.3600 (+3.03%)
Context Therapeutics® Announces Encouraging Preclinical Data from Two Programs to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2022

Lead clinical-stage oral progesterone receptor (PR) antagonist ONA-XR demonstrates strong efficacy across multiple PR+ solid tumor models First...

CNTX : 1.3600 (+3.03%)
Context Therapeutics® to Participate in Two April 2022 Investor Conferences

PHILADELPHIA, April 06, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company...

CNTX : 1.3600 (+3.03%)
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

SPI and WEI are leading our lists today

CNTX : 1.3600 (+3.03%)
TWTR : 53.70 (+0.66%)
BBAI : 1.5600 (+7.59%)
ENSV : 0.2622 (-6.69%)
SPI : 0.4798 (-0.74%)
Context Therapeutics® Reports Full Year 2021 Operating and Financial Results

Investor R&D event on April 13th to highlight new preclinical data to be presented at AACR Annual Meeting Strong cash position following $28.75M...

CNTX : 1.3600 (+3.03%)
Context Therapeutics® Announces Acceptance of Five Abstracts to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2022

Context to host webinar with AACR presenters on Wednesday, April 13, 2022, at 11 a.m. ET...

CNTX : 1.3600 (+3.03%)
Context Therapeutics® to Participate in the Sachs 15th Annual European Life Sciences CEO Forum

PHILADELPHIA, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company...

CNTX : 1.3600 (+3.03%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Context Therapeutics Inc. is a women's oncology company developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. Context Therapeutics Inc. is headquartered in Philadelphia, PA.

See More

Key Turning Points

3rd Resistance Point 1.5067
2nd Resistance Point 1.4533
1st Resistance Point 1.4067
Last Price 1.3600
1st Support Level 1.3067
2nd Support Level 1.2533
3rd Support Level 1.2067

See More

52-Week High 1.6900
Last Price 1.3600
Fibonacci 61.8% 1.2240
Fibonacci 50% 1.0800
Fibonacci 38.2% 0.9360
52-Week Low 0.4700

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar